8-K: Dermata's XYNGARI Shows Strong Phase 3 Acne Efficacy

Dermata Therapeutics presented positive clinical data for its XYNGARI (DMT310) Phase 3 STAR-1 trial, demonstrating statistically significant improvements in acne treatment.

Summary

• Dermata Therapeutics, Inc. (DRMA) disclosed clinical data from its XYNGARI (DMT310) Phase 3 Spongilla Treatment of Acne (STAR-1) clinical trial.
• The data was presented in an abstract at the European Academy of Dermatology and Venereology Congress 2025.
• XYNGARI showed statistically significant differences compared to placebo across multiple endpoints at weeks 4, 8, and 12.
• Key endpoints included Investigator Global Assessment (IGA) treatment success, mean change in inflammatory lesion count, percent change in inflammatory lesion count, mean change in non-inflammatory lesion count, and percent change in non-inflammatory lesion count.
• For IGA treatment success (2-point reduction AND score of 0 or 1), XYNGARI achieved 29.4% at Week 12 compared to 15.2% for placebo (P < 0.001).
• For mean change from baseline in inflammatory lesion count, XYNGARI showed a -16.8 reduction at Week 12 compared to -13.1 for placebo (P < 0.001).
• For percent change from baseline in inflammatory lesion count, XYNGARI achieved 59.1% at Week 12 compared to 45.3% for placebo (P < 0.001).
• For mean change from baseline in non-inflammatory lesion count, XYNGARI showed a -17.3 reduction at Week 12 compared to -12.4 for placebo (P < 0.001).
• For percent change from baseline in non-inflammatory lesion count, XYNGARI achieved 48.3% at Week 12 compared to 34.7% for placebo (P < 0.001).

Sentiment

Score: 9

Explanation: The filing reports highly positive Phase 3 clinical trial results for XYNGARI, demonstrating statistically significant efficacy across all key endpoints for acne treatment. This is a critical milestone for the company and its lead product candidate.

Positives

• XYNGARI demonstrated statistically significant improvements in Investigator Global Assessment (IGA) treatment success at weeks 4, 8, and 12 compared to placebo (P < 0.05 to P < 0.001).
• Significant reductions in both inflammatory and non-inflammatory lesion counts were observed with XYNGARI at all measured time points (weeks 4, 8, 12) compared to placebo (P < 0.001 for all lesion count metrics).
• The consistent statistical significance across multiple primary and secondary endpoints indicates a robust treatment effect for XYNGARI in acne.
• Presentation of these positive Phase 3 clinical data at a major dermatology congress enhances the credibility and visibility of XYNGARI.

Future Outlook

The filing indicates the successful presentation of positive Phase 3 clinical data for XYNGARI, suggesting progress towards potential regulatory submissions and commercialization for the acne treatment.

Management Comments

• The Company observed statistically significant differences in IGA treatment success, mean change in inflammatory lesion count, and non-inflammatory lesion count, as well as percent change in inflammatory lesion count and non-inflammatory lesion count at week 4, 8, and 12 when compared to placebo.

Industry Context

The dermatology market for acne treatments is substantial and competitive. Positive Phase 3 data, especially demonstrating statistically significant improvements across multiple key endpoints, positions XYNGARI as a potentially strong contender in this space. Such results are critical for differentiation and market entry in a therapeutic area with existing established treatments.

Comparison to Industry Standards

• The statistically significant improvements in IGA treatment success and lesion count reductions observed for XYNGARI are generally considered strong indicators of efficacy in dermatology clinical trials, aligning with benchmarks for successful Phase 3 outcomes in acne treatments.
• While direct comparisons to specific competitor drugs like topical retinoids (e.g., tretinoin, adapalene) or oral antibiotics are not provided in the filing, achieving P < 0.001 for most lesion count metrics at Week 12 suggests a clinically meaningful effect size that could be competitive.
• The IGA success rates of 29.4% (2-point reduction AND score of 0 or 1) and 34.3% (2-point reduction) at Week 12 for XYNGARI are favorable and would be assessed against similar metrics reported by other approved acne therapies in their pivotal trials.

Stakeholder Impact

• Shareholders: Positive clinical trial results typically lead to increased investor confidence and potential share price appreciation, as it de-risks the product's path to market.
• Patients: The positive data suggests a new, effective treatment option for individuals suffering from acne, potentially improving quality of life.
• Healthcare Providers: The data provides evidence for a new therapeutic option that could be integrated into clinical practice for acne management.

Next Steps

• Presentation of the abstract containing clinical data at the European Academy of Dermatology and Venereology Congress 2025.

Key Dates

Recommendation

The reported Phase 3 clinical trial results for XYNGARI are unequivocally positive, demonstrating statistically significant efficacy across all primary and secondary endpoints in acne treatment. This is a major de-risking event for Dermata Therapeutics' lead product candidate and significantly enhances its commercial potential. Strong Phase 3 data is a critical milestone for regulatory approval and market entry, suggesting a substantial increase in the company's intrinsic value and future revenue prospects. This news is highly likely to drive significant positive share price movement.

Keywords

Dermata Therapeutics, XYNGARI, DMT310, Acne Treatment, Phase 3 Clinical Trial, STAR-1, Dermatology, Clinical Data, Spongilla, IGA Treatment Success, Lesion Count Reduction